Roluperidone not checked
Minerva Neurosciences · MIN-101
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Negative Symptoms of Schizophrenia
- Main trialPhase 3
- “Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate of Roluperidone and antipsychotic medications.”In the company’s words, NCT07565428 on ClinicalTrials.gov
- Other names
- MIN-101
Other drugs for Negative Symptoms of Schizophrenia
- ACP-204ACADIA Pharmaceuticals Inc. · Phase 3
- ML-007C-MAMapLight Therapeutics · Phase 2
- LY03017Luye Pharma Group Ltd. · Phase 1
Coming up1
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications | |
| Phase 3Completed | 26 May 2020 | Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia | |
| Phase 1Completed | 12 Jan 2024 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026